Biogen Investors Say Co. Misled Them On Alzheimer's Drug
Biogen Inc. investors on Friday hit the drugmaker with a putative class action claiming the company and its top brass misled shareholders about the effectiveness of aducanumab, a proposed drug for...To view the full article, register now.
Already a subscriber? Click here to view full article